ArunSanyalMD

Gastroenterology • Richmond, VA

Hepatology & Liver Transplantation

Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine

Join to view full profile

Dr. Sanyal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sanyal's full profile

Already have an account?

Office
1250 E Marshall St
Richmond, VA 23298
Phone+1 804-828-6314

Fax+1 804-828-2992
Is this information wrong?

Education & Training

Virginia Commonwealth University Health SystemFellowship, Gastroenterology, 1987 - 1989
Texas Tech University (Amarillo)Residency, Internal Medicine, 1984 - 1987
Maulana Azad Medical CollegeClass of 1981

Certifications & Licensure

VA State Medical License 1986 - 2026
NM State Medical License 1986 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Clinical Trials

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Start of enrollment: 2006 May 01
Completed
Phase 3
Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Start of enrollment: 2006 Dec 01
Terminated
Phase 3
BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis Start of enrollment: 2008 Aug 01
Completed
Phase 3
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Start of enrollment: 2009 Dec 02
Completed
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Start of enrollment: 2010 Sep 01
Completed
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT) Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Hepatitis B Research Network Adult Cohort Study Start of enrollment: 2010 Dec 01
Completed
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients Start of enrollment: 2011 Oct 01
Completed
Phase 2
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic Steatohepatitis Start of enrollment: 2012 Dec 01
Withdrawn
Phase 2
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Start of enrollment: 2013 Apr 03
Terminated
Phase 4
Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest Start of enrollment: 2013 Sep 01
Completed
Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis Start of enrollment: 2014 Dec 01
Completed
Phase 2
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) Start of enrollment: 2014 Nov 03
Terminated
Phase 2
Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium Start of enrollment: 2013 Jun 01
Completed
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Start of enrollment: 2015 Aug 01
Completed
Phase 2
Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese Start of enrollment: 2018 Apr 01
Not yet recruiting
Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis Start of enrollment: 2019 Apr 16
Completed
Phase 2
A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Start of enrollment: 2019 Sep 23
Completed
Phase 2
Non-Invasive Quantification of Liver Health in NASH (N-QUAN) Start of enrollment: 2020 Aug 05
Recruiting
Not Applicable
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis Start of enrollment: 2020 Jul 10
Completed
Phase 2
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency Start of enrollment: 2019 Mar 30
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and oth...
Mansoor Husain, Crystel Diab, Kamal Kant Mangla, Ahsan Shoeb, Arun J Sanyal, Ildiko Lingvay, Elliot B Tapper> ;American Heart Journal Plus. 2024 May 1
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease.
Eduardo Vilar-Gomez, Katherine P Yates, Laura A Wilson, James Tonascia, Naga Chalasani, Rohit Loomba, Anna Mae Diehl, Brent A Neuschwander-Tetri, Srinivasan Dasarathy,...> ;Hepatology. 2024 Apr 23
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
Quentin M Anstee, Jeremy Magnanensi, Yacine Hajji, Alexandra Caron, Zouher Majd, Christian Rosenquist, Dean W Hum, Bart Staels, Margery A Connelly, Rohit Loomba, Steph...> ;JHEP Reports. 2024 Apr 1
The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
Stephen A Harrison, Manal F Abdelmalek, Arun J Sanyal> ;Diabetes, Obesity & Metabolism. 2024 Mar 21
2 citations
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.
Huapeng Lin, Hye Won Lee, Terry Cheuk-Fung Yip, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström, Jérôme Bour...> ;JAMA. 2024 Apr 16
1 citations
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.
Michail Kokkorakis, Chrysoula Boutari, Michael A Hill, Vasilios Kotsis, Rohit Loomba, Arun J Sanyal, Christos S Mantzoros> ;Metabolism. 2024 May 1
Emerging therapies for MASLD and their impact on plasma lipids.
Dixon, D., Nguyen, M., Asgharpour, A., Sanyal, A., Mehta, A.> ;American Journal of Preventive Cardiology. 2024 Mar 1
1 citations
Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis.
Samer Gawrieh, Srinivasan Dasarathy, Wanzhu Tu, Patrick S Kamath, Naga P Chalasani, Craig J McClain, Ramon Bataller, Gyongyi Szabo, Qing Tang, Svetlana Radaeva, Bruce ...> ;Journal of Hepatology. 2024 May 1
4 citations
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
Loomba, R., Vlad Ratziu, Marcus Hompesch, Mathieu Petitjean, Cindy Serdjebi, Janani S Iyer, Anil V Parwani, Dean Tai, Elisabetta Bugianesi, Kenneth Cusi, Scott L Fried...> ;Journal of Hepatology. 2024 Feb 1
Uncoupler therapy for NAFLD: is flushing a possible harbinger of a safety concern? - Authors' reply.
Jorkasky, D., Khan, S., Noureddin, M., Sanyal, A.> ;The Lancet. Gastroenterology & Hepatology. 2024 Feb 1
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement.
Hagström, H., Adams, L., Allen, A., Byrne, C., Chang, Y., Duseja, A., Grønbæk, H., Ismail, M., Jepsen, P., Kanwal, F., Kramer, J., Loomba, R., Mark, H., Newsome, P., R...> ;Hepatology Communications. 2024 Feb 1
2 citations
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Mazen Noureddin, Emily Truong, Rebeca Mayo, Ibon Martínez-Arranz, Itziar Mincholé, Jesus M Banales, Marco Arrese, Kenneth Cusi, María Teresa Arias-Loste, Radan Bruha, ...> ;Hepatology. 2024 Jan 1
1 citations
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.
Anstee, Q., Ratziu, V., Rinella, M., Harrison, S., Capozza, T., Sawhney, S., Shelat, N., Sanyal, A., Loomba, R., Kowdley, K., Resnick, M., Younossi, Z.> ;Hepatology Communications. 2024 Jan 1
Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD.
Loomba, R., Chaowapong Jarasvaraparn, Eduardo Vilar-Gomez, Katherine P Yates, Laura A Wilson, Brent Neuschwander-Tetri, Rohit Loomba, Oscar Cummings, Miriam Vos, Stavr...> ;Clinical Gastroenterology and Hepatology. 2024 May 1
Machine-learning model comprising five clinical indices and liver stiffness measurement can accurately identify MASLD-related liver fibrosis.
Fan, R., Yu, N., Li, G., Arshad, T., Liu, W., Wong, G., Liang, X., Chen, Y., Jin, X., Leung, H., Chen, J., Wang, X., Yip, T., Sanyal, A., Sun, J., Wong, V., Zheng, M.,...> ;Liver International. 2024 Mar 1
3 citations
NIS2+as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.
Ratziu, V., Harrison, S., Hajji, Y., Magnanensi, J., Petit, S., Majd, Z., Delecroix, E., Rosenquist, C., Hum, D., Staels, B., Anstee, Q., Sanyal, A.> ;Journal of Hepatology. 2024 Feb 1
3 citations
Rising global burden of cancer attributable to high BMI from 2010 to 2019.
Darren Jun Hao Tan, Cheng Han Ng, Mark Muthiah, Jie Ning Yong, Douglas Chee, Margaret Teng, Zhen Yu Wong, Rebecca Wenling Zeng, Yip Han Chin, Jiong-Wei Wang, Pojsakorn...> ;Metabolism. 2024 Mar 1
Cholestenoic acid as endogenous epigenetic regulator decreases hepatocyte lipid accumulation in vitro and in vivo.
Yaping Wang, Phillip B Hylemon, Hae-Ki Min, John Min, Michael Fuchs, Arun J Sanyal, Shunlin Ren, Pandak, W.> ;American Journal of Physiology. Gastrointestinal and Liver Physiology. 2024 Feb 1
2 citations
A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.
Philip N Newsome, Arun J Sanyal, Guy Neff, Jörn M Schattenberg, Vlad Ratziu, Judith Ertle, Jasmin Link, Alison Mackie, Corinna Schoelch, Eric Lawitz> ;Nature Communications. 2023 Nov 6
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver...
Melissa Palmer, David E Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I Avigan, Arie Regev, Paul H Hayashi, James H Lewis, Ruby Mehta, Stephen A Harrison, Massimo Si...> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
7 citations
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, pha...
Mazen Noureddin, Shaharyar Khan, Francisco Portell, Diane Jorkasky, Jameel Dennis, Omer Khan, Lars Johansson, Edvin Johansson, Arun J Sanyal> ;The Lancet. Gastroenterology & Hepatology. 2023 Dec 1
1 citations
Digital pathology for nonalcoholic steatohepatitis assessment.
Arun J Sanyal, Prakash Jha, David E Kleiner> ;Nature Reviews. Gastroenterology & Hepatology. 2024 Jan 1
9 citations
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, Mazen Noureddin, Arun J Sanyal, Jörn M Schattenberg, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub...> ;Alimentary Pharmacology & Therapeutics. 2024 Jan 1
3 citations
Foregut bypassrestrictive bariatric procedures for nonalcoholic fatty liver disease: a meta-analysis of 3,355 individuals.
Wen Hui Lim, Snow Yunni Lin, Cheng Han Ng, Darren Jun Hao Tan, Jieling Xiao, Jie Ning Yong, Phoebe Wen Lin Tay, Nicholas Syn, Yip Han Chin, Kai En Chan, Chin Meng Khoo...> ;Hepatobiliary Surgery and Nutrition. 2023 Oct 1
2 citations
Natural history of NASH cirrhosis in liver transplant waitlist registrants.
Lim, W., Ng, C., Tan, D., Tseng, M., Xiao, J., Yong, J., Zeng, R., Cho, E., Tay, P., Ang, C., Koh, J., Teng, M., Syn, N., Kow, A., Huang, D., Tan, E., Rinella, M., San...> ;Journal of Hepatology. 2023 Oct 1
Join now to see all

Journal Articles

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19
Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Arun J Sanyal, Gregory Huhn, JAMA
The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet
HSD17B13 Is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non‐Alcoholic Fatty Liver Disease
Elizabeth K Speliotes, Arun J Sanyal, Hepatology
Mechanisms of NAFLD Development and Therapeutic Strategies
Arun J Sanyal, Mary Rinella, Scott L Friedman, Nature
Recent Advances in Understanding and Managing Non-Alcoholic Fatty Liver Disease
Somaya Albhaisi, Arun Sanyal, F1000Research
Proton Pump Inhibitor Initiation and Withdrawal Affects Gut Microbiota and Readmission Risk in Cirrhosis
Michael Fuchs, Puneet Puri, Mohammad S Siddiqui, Douglas M Heuman, Jasmohan S Bajaj, Arun J Sanyal, Velimir Luketic, Richard K Sterling, Nature
Join now to see all

Lectures

Evaluation of Acute Kidney Injury in a Cirrhotic Patient: HRS and Beyond
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Future Therapies for NAFLD/NASH
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
Advances in the Management of Cirrhosis and Portal Hypertension
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018

Other

A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-11-20
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2013-04-05
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-06-27
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-12-17
A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
Arun Sanyal, MD, Hepatology
https://www.doximity.com/articles/bc75785f-aec8-48b3-bbeb-34d8e6413d27
UpToDate, Wolters Kluwer Health - 2012-09-10
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2013-04-05
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2012-08-20
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2012-10-18
Putting Non-Alcoholic Fatty Liver Disease on the Radar for Primary Care Physicians: How Well Are We Doing?
Arun Sanyal, MD, BioMed Central
https://www.doximity.com/articles/59f5dcf3-ca8b-4736-9f3e-ae9fc8833546
UpToDate, Wolters Kluwer Health - 2013-01-02
Join now to see all

Authored Content

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020

Press Mentions

Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASHMarch 30th, 2023
Gaining Momentum for Liver Care: Arun Sanyal Reflects on the VCU Liver Institute’s First YearFebruary 15th, 2023
VCU Researchers Provide New Insights for Combating Fatty Liver Disease at Inaugural SymposiumDecember 9th, 2022
Join now to see all